Loading clinical trials...

Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS

NCT02124941•Yale University

Summary

This study is designed to look at the relationship between brain glucose utilization, neurotransmission (e.g., glutamate, also known as the main excitatory amino-acid neurotransmitter in the brain), and synaptic density. This relationship will be explored in the brain's prefrontal cortex, an area important in decision-making and impulsivity.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Age 18-55 years;
•2. Voluntary, written, informed consent;
•3. Physically healthy by medical history, physical, neurological, ECG and laboratory examinations;
•4. DSM-IV criteria for Cocaine Dependence (304.20) (Note: subjects will also meet DSM-5 criteria for Cocaine Use Disorder);
•5. Documented evidence (by urine toxicology) of abstinence from cocaine (2 weeks for scan 1, and 2 and 4 weeks for scans 2 and 3, respectively)
•6. Full scale and verbal IQs \> 80;
•7. For females, a negative serum pregnancy test (β-HCG) at screening and negative urine pregnancy test on PET scan day prior to imaging.

Exclusion Criteria

•1. A history of other substance dependence (e.g., alcohol, opiates, sedative hypnotics), except for nicotine;
•2. A primary DSM-IV Axis I major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depression, etc.) as determined by the Structured Clinical Interview for DSM-IV (SCID);
•3. A history of significant medical (e.g., cardiovascular, diabetic/metabolic) or neurological (e.g., cerebrovascular, seizure, traumatic brain injury) illness;
•4. Current use of psychotropic and/or potentially psychoactive prescription medications;
•5. Medical contraindications to participation in a magnetic resonance imaging procedure (e.g., ferromagnetic implants/foreign bodies, claustrophobia, cardiac pacemaker, prosthetic valve, otologic implant, etc.);
•6. For females, laboratory (β-HCG) evidence of pregnancy, physical evidence of pregnancy;
•7. For subjects interested in pharmacotherapy component, history of allergies to NAC and current elevation on liver function tests above twice the normal limit;
•8. Subjects with history of prior radiation exposure for research purposes within the past year such that participation in this study would place them over FDA limits for annual radiation exposure. This guideline is an effective dose of 5 rem received per year;
•9. Subjects with current, past or anticipated exposure to radiation in the work place within one year of proposed research PET scans;
•10. History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto);
+1 more criteria

Locations (1)

Connecticut Mental Health Center

New Haven, Connecticut, United States

Key Dates

Start Date

February 1, 2014

Primary Completion Date

August 14, 2022

Completion Date

August 14, 2022

Last Updated

July 7, 2023

Enrollment

ACTUAL participants

Conditions

Cocaine DependenceHealthy

Interventions

N-acetyl cysteine

DRUG

[18F]FDG PET scan

DIAGNOSTIC_TEST

1H MRS

DIAGNOSTIC_TEST

[11C]APP311 PET scan

DIAGNOSTIC_TEST

Collection of Data and Samples From Healthy Donors for Use in Translational Research

NCT00090662

Healthy Volunteer

View study

RECRUITINGPHASE1/PHASE2

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.

NCT06290258

Autism Spectrum DisorderGastrointestinal Diseases+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 7, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS

Inclusion Criteria

Exclusion Criteria

Collection of Data and Samples From Healthy Donors for Use in Translational Research

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.

A New Portable Device for Non-invasive Ventilatory Support

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Turkish Validity and Reliability Study of PRevention of Toxic Chemicals in the Environment for Children Tool

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity